Stallergenes Greer
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| File:Stallergenes.jpg | |
| Company type | Public (Euronext: STAGR) |
|---|---|
| Founded | 2015 |
| Headquarters | London, United Kingdom |
Key people | Fereydoun Firouz (Chief Executive Officer) Peter Bühler (Chief Financial Officer) |
| Revenue |  € 186.4 million (2016) [1] |
Number of employees | > 1,400 |
Stallergenes Greer plc is a global biopharmaceutical company headquartered in London, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.
Stallergenes Greer plc is the parent company of GREER Laboratories, Inc.[2] (registered office is in the U.S.) and Stallergenes S.A.S. (registered office in France).[3]
History
Stallergenes, established 1962,[4] was a French pharmaceutical company headquartered in Antony, Hauts-de-Seine. The founder was Institut Mérieux in Lyon (France). In 2015 Stallergenes, previously headquartered in Antony, Hauts-de-Seine, and U.S. Greer Laboratories, Inc. merged to form Stallergenes Greer headquartered in London, "a worldwide leader in allergy immunotherapy".[5][6]
Greer dates was founded by R.T. Greer, a collecter of source materials (i.e. : roots, herbs, pollens) in 1904.[7]
Executive committee
The board of directors includes:[8]
- Fereydoun Firouz Chairman & CEO Executive Director
- Jean-Luc Belingard Independent Director
- Rodolfo Bogni Director
- Patrick Langlois Independent Director
- Stefan Meister Director
- Paola Ricci Executive Director, Head of Pharmaceutical Affairs
- Yvonne Schlaeppi Independent Director
- Elmar Schnee Independent Director
Previous CEOs of Stallergenes include Michele Antonelli and Christian Chavy.
A pharmaceutical and clinical development programme
Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies around the world.[citation needed]
Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.[citation needed]
The second project in this programme is the house dust mite immunotherapy tablet:[citation needed]
Three other projects intended for the treatment of allergic rhinitis caused by birch pollen, Japanese cedar and ragweed pollen are currently under development.[citation needed]
References
- ^ "Annual report" (PDF). stallergenesgreer.com. 2016.
- ^ "Stallergenes Greer - Life beyond allergy". Stallergenes Greer.
- ^ "LinkedIn". www.linkedin.com.
- ^ "Linked In: Stallergenes".
- ^ "About Us - stallergenesgreer.com". www.stallergenesgreer.com.
- ^ "Stallergenes and Greer to create the World Leader in Allergy Immunotherapy - Labiotech.eu". 30 June 2015.
- ^ "History - stallergenesgreer.com". stallergenesgreer.com.
- ^ [1][dead link]